Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: A potential mechanism of tumor-immune privilege

Cancer Cell

Volumn 5, Issue 3, 2004, Pages 241-251

  Rubinstein, Natalia ^a,b   Alvarez, Mariano ^b   Zwirner, Norberto W ^a,b   Toscano, Marta A ^a,b   Ilarregui, Juan M ^a,b   Bravo, Alicia ^c   Mordoh, José ^b   Fainboim, Leonardo ^a,b   Podhajcer, Osvaldo L ^b   Rabinovich, Gabriel A ^a,b  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Hospital Eva Peron   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; WILD TYPE;

ANIMALIA;

EID: 12144285871     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00024-8     Document Type: Article

References (60)

1. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., Squarcina P., Accornero P., Lozupone F., Lugini L.et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195:2002;1303-1316.
2. Blaser C., Kaufmann M., Muller C., Zimmermann C., Wells V., Mallucci L., Pircher H. β-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur. J. Immunol. 28:1998;2311-2319.
3. Boon T., van den Eynde B. Tumor immunology. Curr. Opin. Immunol. 15:2003;129-130.
4. Camby I., Belot N., Rorive S., Lefranc F., Maurage C.A., Lahm H., Kaltner H., Hadari Y., Ruchoux M., Brotchi J.et al. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, anaplastic astrocytomas and glioblastomas and significantly modulate tumor astrocyte migration. Brain Pathol. 11:2001;12-16.
5. Cheng F., Wang H.-W., Cuenca A., Huang M., Ghansah T., Brayer J., Kerr W.G., Takeda K., Akira S., Schoenberger S.P.et al. A critical role for Stat3 signaling in immune tolerance. Immunity. 19:2003;425-436.
6. Chung C.D., Patel V.P., Moran M., Lewis L.A., Miceli M.C. Galectin-1 induces partial TCR ξ-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol. 165:2000;3722-3729.
7. Cindolo L., Benvenuto G., Salvatore P., Pero R., Salvatore G., Mirone V., Prezioso D., Altieri V., Bruni C.B., Chiariotti L. Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Cancer. 84:1999;39-43.
8. Daniels M.A., Hogquist K.A., Jameson S.C. Sweet 'n' sour. the impact of differential glycosylation on T cell responses Nat. Immunol. 3:2002;903-910.
9. Dias-Baruffi M., Zhu H., Cho M., Karmakar S., McEver R.P., Cummings R.D. Dimeric galectin-1 induces surface exposure of phosphatidylserine and phagocytic recognition of leukocytes without inducing apoptosis. J. Biol. Chem. 278:2003;41282-41293.
10. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 413:2001;165-171.
11. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., Lennon V.A. Tumor-associated B7-H1 promotes T-cell apoptosis. A potential mechanism of immune evasion Nat. Med. 8:2002;793-800.
12. Duguay D., Mercier F., Stagg J., Martineau D., Bramson J., Servant M., Galipeau J., Hiscott J. In vivo IRF-3 tumor suppressor activity in B16 melanoma tumors. Cancer Res. 62:2002;5148-5152.
13. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting. from immunosurveillance to tumor escape Nat. Immunol. 3:2002;991-998.
14. Feizi T. Progress in deciphering the information content of the glycome. a crescendo in the closing years of the milennium Glycoconj. J. 17:2000;553-565.
15. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., Mellor A.L., Munn D.H., Antonia S.J. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T-cell-mediated rejection. Int. J. Cancer. 101:2002;151-155.
16. Fukumori T., Takenaka Y., Yoshii T., Kim H.C., Hogan V., Inohara H., Kagawa S., Raz A. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 63:2003;8302-8311.
17. Ghosh P., Komschlies K.L., Cippitelli M., Longo D.L., Subleski J., Ye J., Sica A., Young H.A., Wiltrout R.H., Ochoa A.C. Gradual loss of T-helper 1 populations in spleens of mice during progressive tumor growth. J. Natl. Cancer Inst. 87:1995;1478-1483.
18. Gorelik L., Flavell R.D. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:2001;1118-1122.
19. Green D.R., Ferguson T.A. The role of Fas ligand in immune privilege. Nat. Rev. Mol. Cell Biol. 2:2001;917-924.
20. Guerra L., Mordoh J., Slavutsky I., Larripa I., Medrano E. Characterization of IIB-Mel-J. a new and highly heterogeneous human melanoma cell line Pigment Cell Res. 2:1989;504-509.
21. Hahne M., Rimoldi D., Schröter M., Romero P., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J.C., Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand. Implications for tumor immune escape Science. 274:1996;1363-1366.
22. Hu H.M., Urba W.J., Fox B.A. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type-2 to a type-1 cytokine profile. J. Immunol. 161:1998;3033-3041.
23. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4+ T cells in the anti-tumor immune response. J. Exp. Med. 188:1998;2357-2368.
24. Igney F.H., Krammer P.H. Immune escape of tumors. apoptosis resistance and tumor counterattack J. Leukoc. Biol. 71:2002;907-920.
25. Kariyama C., Slavutsky I., Larripa I., Morvillo V., Bravo A.I., Bover L., Podhajcer O.L., Mordoh J. Biologic, immunocytochemical and cytogenetic characterization of two new melanoma cell lines. IIB-Mel-LES and IIB-Mel-IAN Pigment Cell Res. 8:1995;121-131.
26. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., Smyth M.I. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3:2002;83-90.
27. Kopitz J., von Reitzenstein C., André S., Kaltner H., Uhl J., Ehemann V., Cantz M., Gabius H.-J. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J. Biol. Chem. 276:2001;35917-35923.
28. Lahm H., André S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic purposes. J. Cancer Res. Clin. Oncol. 127:2001;375-386.
29. Ledda M.F., Adris S., Bravo A.I., Kariyama C., Bover L., Chernajovsky Y., Mordoh J., Podhajcer O.L. Supression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 3:1997;171-176.
30. Liu F.-T. Galectins. a new family of regulators of inflammation Clin. Immunol. 97:2000;79-88.
31. Lowe J.B. Glycosylation, immunity and autoimmunity. Cell. 104:2001;809-812.
32. Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T-cell recognition. molecular mechanisms and significance Adv. Immunol. 74:2000;181-273.
33. Morvillo V., Bover L., Mordoh J. Identification and characterization of a 14 kDa immunosuppressive protein derived from IIB-Mel-J, a human melanoma cell line. Cell Mol. Biol. 42:1996;779-795.
34. Nguyen J.T., Evans D.P., Galvan M., Pace K.E., Leitenberg D., Bui T.N., Baum L.G. CD45 modulates galectin-1-induced T cell death. regulation by expression of core 2 O-glycans J. Immunol. 167:2001;5697-5707.
35. O'Connell J., Houston A., Bennett M.W., O'Sullivan G.C., Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat. Med. 7:2001;271-274.
36. Pardoll D. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2:2002;227-238.
37. Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21:2003;807-839.
38. Perillo N.L., Pace K.E., Seilhamer J.J., Baum L.G. Apoptosis of T cells mediated by galectin-1. Nature. 378:1995;736-739.
39. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J.et al. Cancer regression and autoimmunity induced by CTLA-4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 100:2003;8372-8377.
40. Rabinovich G.A. Galectins. an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy Cell Death Differ. 6:1999;711-721.
41. Rabinovich G.A., Iglesias M.M., Modesti N.M., Castagna L.F., Wolfenstein-Todel C., Riera C.M., Sotomayor C.E. Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells. biochemical and functional characterization J. Immunol. 160:1998;4831-4840.
42. Rabinovich G.A., Daly G., Dreja H., Tailor H., Riera C.M., Hirabayashi J., Chernajovsky Y. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med. 190:1999;385-397. a.
43. Rabinovich G.A., Ariel A., Hershkoviz R., Hirabayashi J., Kasai K.I., Lider O. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology. 97:1999;100-106. b.
44. Rabinovich G.A., Baum L.G., Tinari N., Paganelli R., Natoli C., Liu F.-T., Iacobelli S. Galectins and their ligands. amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23:2002;313-320. a.
45. Rabinovich G.A., Ramhorst R.E., Rubinstein N., Corigliano A., Daroqui C., Bal de Kier E., Fainboim L. Induction of allogeneic T-cell hyporesponsiveness by a galectin-1-mediated apoptotic and non-apoptotic mechanisms. Cell Death Differ. 9:2002;661-670. b.
46. Ramirez-Montagut T., Turk M.J., Wolchok J.D., Guevara-Patino J.A., Houghton A.N. Immunity to melanoma. unraveling the relation of tumor immunity and autoimmunity Oncogene. 22:2003;3180-3187.
47. Restifo N.P. Countering the "counterattack" hypothesis. Nat. Med. 7:2001;259.
48. Sanjuan X., Fernandez P.L., Castells A., Castronovo V., van den Brule F., Liu F.-T., Cardesa A., Campo E. Differential expression of galectin-3 and galectin-1 in colorectal cancer progression. Gastroenterology. 113:1997;1906-1915.
49. Santucci L., Fiorucci S., Rubinstein N., Mencarelli A., Palazzetti B., Federici B., Rabinovich G.A., Morelli A. Galectin-1 suppresses experimental colitis in mice. Gastroenterology. 124:2003;1381-1394.
50. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFN-γ and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature. 410:2001;1107-1111.
51. Simon A.K., Gallimore A., Jones E., Sawitzki B., Cerundolo V., Screaton G.R. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell. 2:2002;315-322.
52. Smyth M.J., Godfrey D.I., Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2:2001;293-299.
53. Tinari N., Kuwabara I., Huflejt M.E., Shen P.F., Iacobelli S., Liu F.-T. Glycoprotein 90K/Mac-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int. J. Cancer. 91:2001;167-172.
54. Trapani J.A. Tumor-mediated apoptosis of cancer-specific T lymphocytes. Reversing the "kiss of death"? Cancer Cell. 2:2002;169-171.
55. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:2003;1269-1274.
56. van den Brule F., Buicu C., Baldet M., Sobel M.E., Cooper D.N.W., Marschal P., Castronovo V. Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem. Biophys. Res. Commun. 209:1995;760-767.
57. van den Brule F., Waltregny D., Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J. Pathol. 193:2001;80-87.
58. van den Brule F., Califice S., Garnier F., Fernandez P.L., Berchuck A., Castronovo V. Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab. Invest. 83:2003;377-386.
59. Whiteside T.L. Tumor-induced death of immune cells. its mechanisms and consequences Semin. Cancer Biol. 12:2002;43-50.
60. Xu X.C., el-Naggar A.K., Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am. J. Pathol. 147:1995;815-822.